Maxime Cahuzac

Research Advisor at @IRIC_umontreal.

[Maxime Cahuzac @MaximeCahuzac]

I'm very happy to share my second paper published in @Cancers_MDPI! #prostatecancer #parpinhibitor
https://t.co/YoWFXuExV0

[Molecular Cell @MolecularCell]

Mitochondrial protein import stress regulates the LC3 lipidation step of mitophagy through NLRX1 and RRBP1 https://t.co/aCgsYPOjms

[Sécurité incendieMTL @MTL_SIM]

Passez voir les pompières et pompiers du @MTL_SIM à l'angle du boul. Décarie et de la rue Jean-Talon Ouest! Ils recueillent des dons pour @cancermtl. Merci!👩‍🚒🙏👨‍🚒

[Kevin Kaulanjan @KevinKaulanjan]

Thank @cancermtl for such a interesting day. @CRCHUM @MaximeCahuzac @LBrureau #FredSaad #prostatecancer

[Nature Reviews Drug Discovery @NatRevDrugDisc]

Synthetic lethality strategies in oncology exploit cancerous loss-of-function mutations by targeting related pathways. Find out more about the latest advances in the field with targets including PARP1 and ATR in this news story ICYMI https://t.co/N7rNzXz6Lf

[Centre de recherche du CHUM @CRCHUM]

«Tout ce qu'on a de bien aujourd'hui pour les soins aux patients atteints de #cancer, c'est vraiment grâce à la recherche.» —Dr Fred Saad, chef de l'unité d'urologie au @chumontreal et chercheur #CRCHUM.
#FaitesPartieDeLaRecherche
@QConsortium
https://t.co/vtVuOr33V5

[AACR @AACR]

May is National Cancer Research Month.
Basic research drives progress against cancer. The AACR #CancerProgressReport shows how basic research led to the development of PARP inhibitors for the treatment of ovarian cancer: https://t.co/4e2hkLxvzI
#NCRM22 #ResearchSavesLives

[Maxime Cahuzac @MaximeCahuzac]

Dre. Arnoult de @CUBoulderMCDB sera notre conférencière invitée lors de la 31ème journée scientifique de l'Institut du cancer de Montréal le 24 mai prochain. Elle nous parlera de #DNArepair!
@CRCHUM @ArnoultLab
Pour s'inscrire: https://t.co/dD9emlVRv5

[Communications Biology @CommsBio]

A complex involving polarity protein SCRIB and the leucine amino acid transporter SLC7A5 promotes cell proliferation and tamoxifen resistance in estrogen receptor-positive breast cancer cells. @BIDMChealth

https://t.co/V3GQbVfHdR

[nature @Nature]

A new kind of cell division https://t.co/d7PXcGGdA1

[Cancer Drug Resistance @cdrjournal]

Review Article
🌿Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer🌟
https://t.co/YONYe8JTam
@JGrummet @DrSuneil_PCa @Hoomandjaladat
@cpavmd @mrsprostate @DrMartinSanda @AminaZoubeidi

[Cancer Drug Resistance @cdrjournal]

Review Article
🌈Oxidative stress and redox signaling in CRPC progression: therapeutic potential of clinically-tested Nrf2-activators🌸
https://t.co/RbDFFZyjRm
#Prostate cancer #hormone therapy
@DrSuneil_PCa @JuddMoul @Brett_McLeod @FrancescaBZNY @AAytesLab @AminaZoubeidi

[Cancers MDPI @Cancers_MDPI]

🧐In a fruitful collaborative work with Fred Saad lab @CRCHUM @CharlesDariane MD-urologist @HopitalPompidou and PhD Student in @GOFFINVincent2 @NeckerInem identifies keratin-7 as a promising predictive biomarker of #ProstateCancer specific Survival!

Link➡️https://t.co/dabCVRLWWC

[AACR President Keith T. Flaherty @AACRPres]

900-plus speakers, 5,100 poster presenters, and 450 exhibitors.
15,179 in-person attendees and 4,311 virtual attendees. More than 70 countries represented.
Thanks to everyone who participated in #AACR22 and made it a huge success!

[gerry melino @melino_G]

The #caspase-6–p62 axis modulates p62 droplets based #autophagy in a dominant-negative manner… have a read on #CellDeathDifferentiation https://t.co/jh9FVT1pyG

[Maxime Cahuzac @MaximeCahuzac]

Thanks to everyone who checked my poster yesterday at the #AACR22 meeting. It was very exciting to discuss about #autophagy and #PARPi in #prostatecancer !

[AACR @AACR]

Day 3 of #AACR22 showcased the latest advances from across the cancer research continuum—including two clinical trials plenary sessions on Cellular Immunotherapies and Targeting the DNA Damage Response and KRAS.

[Communications Biology @CommsBio]

Pre-activation of autophagy mediates resistance to olaparib by decreasing nuclear SQSTM1/p62, which increases homologous recombination-mediated repair through filamin A expression and BRCA1/Rad51 recruitment. @CRCHUM @UMontreal

https://t.co/Xky6VDkM9L